Crinetics Pharmaceuticals (CRNX) Current Assets (2017 - 2026)

Crinetics Pharmaceuticals' Current Assets history runs 10 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• On a quarterly basis, Current Assets rose 2.43% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 2.43% increase from a year earlier, with the FY2025 full-year figure at $1.0 billion, down 23.78% from the prior year.
• Current Assets rose to $1.3 billion in Q1 2026 per CRNX's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Current Assets topped out at $1.4 billion in Q4 2024 and bottomed at $284.8 million in Q2 2023.
• The 5-year median for Current Assets is $874.8 million (2024), against an average of $779.6 million.
• Across the five-year window, Current Assets slumped 31.58% in 2023 and soared 207.14% in 2024, its largest moves.
• Year by year, Current Assets stood at $345.2 million in 2022, then soared by 66.33% to $574.2 million in 2023, then soared by 139.55% to $1.4 billion in 2024, then declined by 23.78% to $1.0 billion in 2025, then increased by 26.14% to $1.3 billion in 2026.
• Per Business Quant, the three latest CRNX Current Assets figures stand at $1.3 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.1 billion (Q3 2025).